Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (776)	8/1/2000 12:36:39 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1139

dailynews.yahoo.com Tuesday August 1 10:23 AM ET Viagra May Be Effective Diabetes Disorder Treatment NEW YORK (Reuters) - The anti-impotence drug Viagra may also be an effective remedy for a digestive condition common among diabetics, the Wall Street Journal reported on Tuesday. The condition blocks or slows the passage of food from the stomach to the intestine. In its electronic edition, the Journal said a study by researchers at Johns Hopkins University School of Medicine found that Viagra appears to cause an important muscle in the digestive tract to relax in much the way it prompts a muscle in the penis to ease and facilitate an erection. The drug has only been tested in diabetic mice, the newspaper reported, but the results were so encouraging that a pilot study to try it on men and women will be launched as soon as next month. The problem, known as gastroparesis, affects up to 75 percent of diabetics, causing bloating, loss of appetite and in some cases vomiting and dehydration, the Journal said. Gastroparesis also can complicate efforts to control blood-sugar levels with medication because it disrupts the timing of the digestive process, according to the newspaper.Th drug's manufacturer, Pfizer, did not sponsor the research, which was funded by the US Public Health Service and other non-corporate sources. The study appears in August's Journal of Clinical Investigation, the Wall Street Journal said. Shares of Pfizer closed Monday at 43-1/8, off a year high of 49-1/4 but up from a low of 30.